As cited by the research report titled ‘Global Blockbuster Drugs Market 2015 - 2025: Top 50 Drugs Analysis, Deal Trends, Players And Forecasts’, available with MarketStudyReport, global blockbuster drugs market is projected to expand significantly, generating revenues worth USD 292 billion by the end of the forecast duration.
 

Increasing research and development in the pharmaceutical sector along with rising investments are majorly driving global blockbuster drugs market growth.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/1374385/
 

For the record, blockbuster drugs are medications that generate over USD 1 billion revenues in one year for their respective pharmaceutical companies. Many pharmaceutical companies generate profit with the help of right collaboration of work, time, and efforts put in developing these innovative drugs. Thus, if a particular medication  advances to the level of blockbuster drug, then it is a great accomplishment for the pharmaceutical companies and their investors.
 

However, the success for blockbuster drugs is limited to a short period of time due to patent expirations, and this raises some questions about  revenues obtained by pharma companies via development & production of new drugs. Many high revenue generating drugs are likely to face patent expiration in the next few years which will possibly result in declining sales figures. Moreover, stringent regulations and guidelines are resulting in lesser number of drugs being qualified for approval, and this is likely to hinder market development over the forecast duration.
 

Prominent players influencing the global blockbuster drugs industry trends are Biogen Inc., Amgen Inc., Johnson & Johnson, Pfizer Inc., Bristol Myers Squibb, F. Hoffmann-La Roche AG, Merck KGaA, Gilead Sciences Inc., Celgene Corp., AbbVie Inc., Astellas Pharma Inc., C.H. Boehringer Sohn AG & Ko. KG, Incyte Corp., AstraZeneca plc, Eli Lilly and Company, Novartis International AG, GlaxoSmithKline plc, Alexion Pharmaceuticals Inc., Allergan plc, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., and Bayer AG.
 

The report incorporates detailed profiles of the aforementioned players with information on their businesses and product portfolios, along with the latest developments. Experts cite that development of innovative technology-based products will help industry players gain a competitive edge in the market over the forecast timeline.